BRIACELL THERAP (BCTX)
(Delayed Data from NSDQ)
$0.81 USD
-0.43 (-34.68%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $0.84 +0.03 (3.70%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for BRIACELL THERAP falls in the month of July.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -20.30 | -26.84 | -0.43 | -3.68 |
Depreciation/Amortization & Depletion | NA | 0.02 | 0.02 | 0.02 | 0.01 |
Net Change from Assets/Liabilities | NA | -3.53 | -0.39 | -2.28 | 2.44 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 0.07 | 14.73 | -5.05 | 0.07 |
Net Cash From Operating Activities | NA | -23.74 | -12.48 | -7.75 | -1.16 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 3.95 | -3.66 | 65.33 | 1.05 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | -0.09 | -0.36 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | -0.02 | -0.24 | 0.38 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | -0.06 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 3.95 | -3.74 | 65.00 | 1.07 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | -0.04 |
Net Change In Cash & Equivalents | NA | -19.79 | -16.23 | 57.25 | -0.12 |
Cash at Beginning of Period | NA | 41.04 | 57.27 | 0.02 | 0.14 |
Cash at End of Period | NA | 21.25 | 41.04 | 57.27 | 0.02 |
Diluted Net EPS | NA | -1.30 | -1.73 | -0.09 | -5.20 |
Fiscal Year End for BRIACELL THERAP falls in the month of July.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -3.68 | -5.38 | 5.96 | -20.30 |
Depreciation/Amortization & Depletion | NA | 0.01 | 0.01 | 0.00 | 0.02 |
Net Change from Assets/Liabilities | NA | 5.76 | 2.02 | 0.18 | -3.53 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | -22.18 | -11.66 | -13.75 | 0.07 |
Net Cash From Operating Activities | NA | -20.09 | -15.01 | -7.61 | -23.74 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -0.23 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.23 | 0.00 | 0.00 | 0.00 |
Uses of Funds
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.00 | 0.00 | 0.00 | 3.95 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 0.00 | 0.00 | 0.00 | 3.95 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -20.32 | -15.01 | -7.61 | -19.79 |
Cash at Beginning of Period | NA | 21.25 | 21.25 | 21.25 | 41.04 |
Cash at End of Period | NA | 0.94 | 6.24 | 13.65 | 21.25 |
Diluted Net EPS | NA | 0.11 | -0.71 | -0.50 | -0.14 |